These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28642281)

  • 1. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
    Kato S; Krishnamurthy N; Banks KC; De P; Williams K; Williams C; Leyland-Jones B; Lippman SM; Lanman RB; Kurzrock R
    Cancer Res; 2017 Aug; 77(16):4238-4246. PubMed ID: 28642281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
    Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
    Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characterisation of molecular targets in carcinoma of unknown primary.
    Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
    J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary.
    Kolbinger FR; Bernard V; Lee JJ; Stephens BM; Branchi V; Raghav KPS; Maitra A; Guerrero PA; Semaan A
    J Gastrointest Cancer; 2023 Dec; 54(4):1276-1285. PubMed ID: 36862364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
    Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
    Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
    Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
    Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
    Boscolo Bielo L; Belli C; Crimini E; Repetto M; Ascione L; Pellizzari G; Santoro C; Fuorivia V; Barberis M; Fusco N; Rocco EG; Curigliano G
    Oncologist; 2024 Jun; 29(6):504-510. PubMed ID: 38520742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
    Es HA; Mahdizadeh H; Asl AAH; Totonchi M
    Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary.
    Kato S; Weipert C; Gumas S; Okamura R; Lee S; Sicklick JK; Saam J; Kurzrock R
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34778692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
    Varghese AM; Arora A; Capanu M; Camacho N; Won HH; Zehir A; Gao J; Chakravarty D; Schultz N; Klimstra DS; Ladanyi M; Hyman DM; Solit DB; Berger MF; Saltz LB
    Ann Oncol; 2017 Dec; 28(12):3015-3021. PubMed ID: 29045506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
    Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
    Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.
    Ikeda S; Elkin SK; Tomson BN; Carter JL; Kurzrock R
    Cancer Biol Ther; 2019; 20(2):219-226. PubMed ID: 30339521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.
    Riviere P; Fanta PT; Ikeda S; Baumgartner J; Heestand GM; Kurzrock R
    Mol Cancer Ther; 2018 Jan; 17(1):297-305. PubMed ID: 29133621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.
    Beránek M; Sirák I; Vošmik M; Petera J; Drastíková M; Palička V
    Acta Medica (Hradec Kralove); 2016; 59(2):54-8. PubMed ID: 27526306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Carcinoma of Unknown Primary (CUP) Patient Treated Successfully With Immunotherapy Upon Recognition of Deficient Mismatch Repair Signature on Liquid Biopsy: A Case Report.
    Cox RE; Chakrabarti S
    Cureus; 2022 Jul; 14(7):e27184. PubMed ID: 36017278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.